Document is current
Any future updates will be listed below
-
Authors
Zhou, Caicun https://orcid.org/0000-0002-6958-0766
Dong, Xiaorong
Chen, Gongyan
Wang, Zhehai
Wu, Xianghua
Yao, Yu
Zhang, Yiping
Cheng, Ying https://orcid.org/0000-0001-9908-597X
Pan, Hongming
Zhang, Xiaodong
Cui, Jiuwei
Wang, Lifeng
Chen, Xi
Li, Xiaoling
Wang, Ziping
Wang, Qiming
He, Jianxing
Wang, Mengzhao
Yan, Iris
Qian, Li
Xu, Miao
Huang, Xiayu
Sun, Chun
Cai, Jun
Wu, Qiong
Ballinger, Marcus
Kaul, Monika https://orcid.org/0009-0002-8039-5665
Srivastava, Minu K.
-
Funding
Funding for this research was provided by:
F. Hoffman-La Roche, Inc.
- License Information
-
More Information
Article History
Received: 22 July 2024
Accepted: 18 March 2025
First Online: 16 May 2025
Competing interests
: C.Z. received honoraria as a speaker/consultant from Alice, Amoy Diagnostics, AnHeart, Boehringer Ingelheim, C-Stone, Eli Lilly China, Hengrui, Innovent Biologics, LUYE Pharma, Merck Sharp & Dohme, Qilu, Roche, Sanofi and TopAlliance Biosciences Inc. along with advisor fees from Hengrui, Innovent Biologics, Qilu and TopAlliance Biosciences Inc. C.Z. declares non-financial competing interests as the IASLC President-Elect. I.Y., M.X., X.H., J. Cai and Q.Wu are employees of Roche (China) Holding Ltd and own stocks from Roche. L.Q. and C.S. are employees of Roche (China) Holding Ltd. M.B., M.K., M.K.S. are employees of Genentech and own stocks from Roche. The other authors declare no competing interests.
